Regional response leading to tumorigenesis after sulindac in small and large intestine of mice with Apc mutations

Carcinogenesis

Volumn 24, Issue 3, 2003, Pages 605-611

  Yang, Kan ^a   Fan, Kunhua ^a   Kurihara, Naoto ^a   Shinozaki, Hiroharu ^a   Rigas, Basil ^b   Augenlicht, Leonard ^c   Kopelovich, Levy ^d   Edelmann, Winfried ^c   Kucherlapati, Raju ^e   Lipkin, Martin ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b AMERICAN HEALTH FOUNDATION   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; DRINKING WATER; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN BAX; PROTEIN BCL XL; SULINDAC;

ADENOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; CANCER INCIDENCE; CARCINOGENESIS; CECUM; COLON POLYPOSIS; COLON TUMOR; CONTROLLED STUDY; DIETARY INTAKE; FEEDING; GASTROINTESTINAL CARCINOMA; GASTROINTESTINAL TUMOR; GENE MUTATION; LARGE INTESTINE TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVIEW; SMALL INTESTINE TUMOR; TUMOR VOLUME;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BCL-2-ASSOCIATED X PROTEIN; GENES, APC; INTESTINAL NEOPLASMS; INTESTINE, LARGE; INTESTINE, SMALL; MICE; MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SULINDAC;

EID: 0037360331     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/24.3.605     Document Type: Review

References (61)

1. Giovannucci,E., Egan,K.M., Hunter,D.J., Stampfer,M.J., Colditz,G.A., Willett,W.C. and Speizer,F.E. (1995) Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med., 333, 609-614.
2. Smalley,W. and DuBois,R.N. (1997) Colorectal cancer and non-steroidal anti-inflammatory drugs. Adv. Pharmacol., 39, 1-20.
3. Williams,C.S., Smalley,W. and DuBois,R.N. (1997) Aspirin use and potential mechanisms for colorectal cancer prevention. J. Clin. Invest., 100, 1325-1329.
4. Waddell,W.R. and Loughry,R.W. (1983) Sulindac for polyposis of the colon. J. Surg. Oncol., 24, 83-87.
5. Giardiello,F.M., Offerhaus,G.J. and DuBois,R.N. (1995) The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Eur. J. Cancer, 31A, 1071-1076.
6. Shiff,S.J. and Rigas,B. (1997) Nonsteroidal anti-inflammatory drugs and colorectal cancer: evolving concepts of their chemopreventive actions. Gastroenterology, 113, 1992-1998.
7. Takayama,T., Latsuki,S., Takahashi,Y., Ohi,M., Nojiri,S., Sakamaki,S., Kato,J., Kogawa,K., Miyake,H. and Niitsu,Y. (1998) Aberrant crypt foci of the colon as precursors of adenoma and cancer. N. Engl. J. Med., 339, 1277-1284.
8. Labayle,D., Fischer,D., Vielh,P., Drouhin,F., Pariente,A., Bories,C., Duhamel,O., Trousset,M. and Attali,P. (1991) Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology, 101, 635-639.
9. Nugent,K.P., Farmer,K.C., Spigelman,A.D., Williams,C.B. and Phillips,R.K. (1993) Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br. J. Surg., 80, 1618-1619.
10. Giardiello,F.M., Hamilton,S.R., Krush,A.J., Piantadosi,S., Hylind,L.M., Celano,P., Booler,S.V., Robinson,C.R. and Offerhaus,G.J. (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med., 328, 1313-1316.
11. Giardiello,F.M., Offerhaus,J.A., Tersmette,A.C., Hylind,L.M., Krush,A.J., Brensinger,J.D., Booker,S.V. and Hamilton,S.R. (1996) Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors. Gut, 38, 578-581.
12. Winde,G., Schmid,K.W., Schlegel,W., Fischer,R., Osswald,H. and Bunte,H. (1995) Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Dis. Colon Rectum, 38, 813-830.
13. Cruz-Correa,M., Hylind,L.M., Romans,K.E., Booker,S.V. and Giardiello,F.M. (2002) Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology, 122, 641-645.
14. Keller,J.J., Offerhaus,G.J., Polak,M., Goodman,S.N., Zahurak,M.L., Hylind,L.M., Hamilton,S.R. and Giardiello,F.M. (1999) Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac. Gut, 45, 795-796.
15. Giardiello,F.M., Yang,V.W. and Hylind,L.M. (2002) Primary chemoprevention of familial adenomatous polyposis with sulindac. N. Engl. J. Med., 346, 1054-1059.
16. Rao,C.V., Rivenson,A., Simi,B., Zang,E., Kelloff,G., Steele,V. and Reddy,B.S. (1995) Chemoprevention of colon carcinogenesis by sulindac, a non-steroidal anti-inflammatory agent. Cancer Res., 55, 1464-1472.
17. Reddy,B.S., Kawamori,T., Lubet,R.A., Steele,V.E., Kelloff,G.J. and Rao,C.V. (1999) Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process. Cancer Res., 59, 3387-3391.
18. Moser,A.R., Pitot,H.C. and Dove, W.F. (1990) A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science, 247, 322-324.
19. Su,L.K., Kinzler,K.W., Volgelstein,B., Preisinger,A.C., Moser,A.R., Luongo,C., Gould,K.A. and Dove,W.F. (1992) Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science, 256, 668-670.
20. Fodde,R., Edelmann,W., Yang,K. et al. (1994) A targeted chain-termination mutation in the mouse Apc gene results in multiple intestinal tumors. Proc. Natl Acad. Sci. USA, 91, 8969-8973.
21. Yang,K., Edelmann,W., Fan,K., Lau,K., Kolli,B., Fodde,R., Khan,P.M., Kucherlapati,R. and Lipkin,M. (1997) A mouse model of human familial adenomatous polyposis. J. Exp. Zool., 277, 245-254.
22. Oshima,M., Oshima,H., Kitagawa,K., Kobayashi,M., Itakura,C. and Taketo,M. (1995) Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. Proc. Natl Acad. Sci. USA, 92, 4483-4486.
23. Boolbol,S.K., Dannenberg,A.J., Chadburn,A. et al. (1996) Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res., 56, 2556-2560.
24. Beazer-Barclay,Y., Levy,D.B., Moser,R., Dove,W.F, Hamilton,S.R., Vogelstein,B. and Kinzler,K.W. (1996) Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis, 17, 1757-1760.
25. Chiu,C.H., McEntee,M.F. and Whelan,J. (1997) Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis. Cancer Res., 57, 4267-4273.
26. Yang,K., Fan,K., Shinozaki,H., Newmark,H., Edelmann,W., Kucherlapati,R. and Lipkin,L. (1999) Sulindac increases carcinoma development in the colons of mice with Apc mutations. Proc. Am. Cancer Res., 40, 529.
27. Mahmoud,N.N., Bilinski,R.T., Churchill,M.R., Edelmann, W., Kucherlapati,R. and Bertagnolli,M.M. (1999) Genotype-phenotype correlation in murine Apc mutation: differences in enterocyte migration and response to sulindac. Cancer Res., 59, 353-359.
28. Chiu,C.H., McEntee,M.,F. and Whelan,J. (2000) Discordant effect of aspirin and indomethacin on intestinal tumor burden in Apc (Min/+) mice. Prostaglandins Leukot. Essent. Fatty Acids, 62, 269-275.
29. Oshima,M., Murai,N., Kargman,S., Arguello,M., Luc,P., Kwong,E., Taketo,M.M. and Evans,J.F. (2001) Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res., 61, 1733-1740.
30. Niv,Y. and Fraser,G.M. (1994) Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy. Gastroenterology, 107, 854-857.
31. Lynch,H.T., Thorson,A.G. and Smyrk,T. (1995) Rectal cancer after prolonged sulindac chemoprevention. Cancer, 75, 936-938.
32. Matsuhashi,N., Nakajima,A., Shinohara,K., Oka,T. and Yazaki,Y. (1998) Rectal cancer after sulindac therapy for a sporadic adenomatous colonic polyp. Am. J. Gastroenterol., 93, 2261-2266.
33. Tonelli,F., Valanzano,R., Messerini,L. and Ficari,F. (2000) Long-term treatment with sulindac in familial adenomatous polyposis: is there an actual efficacy in prevention of rectal cancer? J. Surg. Oncol., 74, 15-20.
34. Jass,J.R. and Sobin,L. H. (1989) Histological Typing of Intestinal Tumours, 2nd Edn. World Health Organization, Springer-Verlag, Berlin.
35. Muto, T., Kamiya,J., Sawada,T. et al. (1985) Small 'flat adenoma' of the large bowel with special reference to its clinicopathologic features. Dis. Colon Rectum, 28, 847-851.
36. Teixeira,C.R., Tanaka,S., Haruma,K., Yoshihara,M., Sumii,K. and Shimamoto,F. (1996) Flat-elevated colorectal neoplasms exhibit a high malignant potential. Oncology, 53, 89-93.
37. Lynch,H.T., Smyrk, T.C., Lanspa,S.J., Jenkins,J.S., Lynch,P.M., Cavalieri,J. and Lynch,J.F. (1993) Upper gastrointestinal manifestations in families with hereditary flat adenoma syndrome. Cancer, 71, 2709-2714.
38. Cairns,A. and Quirke,P. (1999) Flat adenomas. Br. J. Surg., 86, 1489-1490.
39. 2. Gut, 35, 675-678.
40. Kargman,S.L., O'Neill,G.P., Vickers,P.J., Evans,J.F., Mancini,J.A. and Jothy,S. (1995) Expression of prostaglandin F/H synthase-1 and -2 protein in human colon cancer. Cancer Res., 55, 2556-2559.
41. Williams,C.S., Luongo,C., Radhika,A., Zhang,T., Lamps,L.W., Nanney,L.B., Beauchamp,R.D. and DuBois,R.N. (1996) Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology, 111, 1134-1140.
42. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87, 803-809.
43. Hull,M.A., Booth,J.K., Tisbury,A., Scott,N., Bonefer,C., Markham,A.F. and Colettta,P.L. (1999) Cyclooxygenase 2 is up-regulated and localized to macrophages in the intestine of Min mice. Br. J. Cancer, 79, 1399-1405.
44. Lim,J.T., Piazza,G.A., Han,E.K. et al. (1999) Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem. Pharmacol., 58, 1097-1107.
45. Shiff,A.J., Qiao,L., Tsai,L.-L. and Rigas,B. (1995) Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence and induces apoptosis in HT-29 colon adenocarcinoma cells. J. Clin. Invest., 96, 491-503.
46. Chan,T.A., Morin,P.J., Vogelstein,B. and Kinzler,K.W. (1998) Mechanisms underlying nonsteroidal anti-inflammatory drug-mediated apoptosis. Proc. Natl Acad. Sci. USA, 95, 681-686.
47. Schmelz,E.M., Bushnev,A.S., Dillehay,D.L., Sullards,M.C., Liotta,D.C. and Merrill,A.H. Jr (1999) Ceramide-β-D-glucuronide. Synthesis, digestion and suppression of early markers of colon carcinogenesis. Cancer Res., 59, 5768-5772.
48. Patrignani,P., Santini,G., Sciulli,M.G., Marinacci,R., Fusco,O., Spoletini,L., Natolli,C., Procopio,A. and Maclouf,J. (1999) Cyclooxygenase-independent induction of p21 WAF-1/CIP-1, apoptosis and differentiation by L-745,337 and salicylate in HT-29 colon cancer cells. Adv. Exp. Med. Biol., 469, 555-561.
49. WAF1/cip1 gene enhances Apc-initiated tumor formation and the tumor-promoting activity of a Western-style diet high-risk diet by altering cell maturation in the intestinal mucosa. Cancer Res., 61, 565-569.
50. McEntee,M.F., Chiu,C.-H. and Whelan,J. (1999) Relationship of beta-catenin and Bcl-2 expression to sulindac-induced regression of intestinal tumors in Min mice. Carcinogenesis, 20, 635-640.
51. Lehmann,J.M., Lenhard,J.M., Oliver,B.B., Ringold,G.M. and Kliewer,S.A. (1997) Peroxisome proliferators - activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem., 272, 3406-3410.
52. Huang,Y., He,Q., Hillman,M.J., Rong,R. and Sheikh,M.S. (2001) Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells. Cancer Res., 61, 6918-6924.
53. Elder,D.J., Hague,A., Hicks,D.J. and Paraskeva,C. (1996) Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma cell lines. Cancer Res., 56, 273-276.
54. Piazza,G.A., Rahm,A.K., Finn,T.S., Fryer,B.H., Stoumen,A.L., Pamukcu,R. and Ahnen,D.J. (1997) Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest and p53 induction. Cancer Res., 57, 2452-2459.
55. Zhang,L., Yu,J., Park,B.H., Kinzler,K.W. and Vogelstein,B. (2000) Role of Bax in the Apoptotic response to anticancer agents. Science, 293, 989-992.
56. Shureiqi,I., Chen,D., Lotan,R., Yang,P., Newman,R.A., Fischer,S.M. and Lippman,S.M. (2000) 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res., 60, 6846-6850.
57. Schulze-osthoff,K., Ferrari,D., Los,M., Wesselborg,S. and Peter,M.E. (1998) Apoptosis signaling by death receptors. Eur. J. Biochem., 254, 439-459.
58. Askkenazi,A. and Dixit,V.M. (1999) Apoptosis control by death and decoy receptors. Curr. Opin. Cell Biol., 11, 255-260.
59. Gross,A., McDonnell,J.M. and Korsmeyer,S.J. (2000) BCL-2 family members and the mitochondria in apoptosis. Genes Dev., 13, 1899-1911.
60. Williams,C.S., Mann,M. and DuBois,R.N. (1999) The role of cyclooxygenases in inflammation, cancer and development. Oncogene, 18, 7908-7915.
61. Yang,K., Fan,K., Lia,M., Edelmann,W., Augenlicht,L.H., Lubet,L., Kopelovich,L., Kucherlapati,R. and Lipkin,M. (2001) Sulindac increases tumor development in the colon of mice with Mlh1 +/- mutation. Proc. Am. Assoc. Cancer Res., 42, 264.